In last trading session, Aquestive Therapeutics Inc (NASDAQ:AQST) saw 1.45 million shares changing hands with its beta currently measuring 2.75. Company’s recent per share price level of $3.06 trading at $0.03 or 0.99% at ring of the bell on the day assigns it a market valuation of $279.01M. That closing price of AQST’s stock is at a discount of -103.59% from its 52-week high price of $6.23 and is indicating a premium of 26.8% from its 52-week low price of $2.24.

For Aquestive Therapeutics Inc (AQST), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.

Aquestive Therapeutics Inc (NASDAQ:AQST) trade information

Upright in the green during last session for gaining 0.99%, in the last five days AQST remained trading in the red while hitting it’s week-highest on Thursday, 02/13/25 when the stock touched $3.06 price level, adding 15.7% to its value on the day. Aquestive Therapeutics Inc’s shares saw a change of -14.04% in year-to-date performance and have moved -9.73% in past 5-day. Aquestive Therapeutics Inc (NASDAQ:AQST) showed a performance of -4.67% in past 30-days.

Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 69.4% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -226.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -226.8% for stock’s current value.

Aquestive Therapeutics Inc (AQST) estimates and forecasts

This year revenue growth is estimated to rise 13.67% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.11M for the same. And 6 analysts are in estimates of company making revenue of 12.9M in the next quarter. Company posted 13.21M and 12.05M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.61% during past 5 years.

Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders

BRATTON CAPITAL MANAGEMENT, L.P. is the top institutional holder at AQST for having 9.81 million shares of worth $25.51 million. And as of 2024-06-30, it was holding 10.7918 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 5.45 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4099 of outstanding shares, having a total worth of $14.18 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.4 shares of worth $7.36 million or 2.64% of the total outstanding shares. The later fund manager was in possession of 2.08 shares on Nov 30, 2024 , making its stake of worth around $6.37 million in the company or a holder of 2.28% of company’s stock.